Citadel Advisors
VERA icon

Citadel Advisors’s Vera Therapeutics VERA Stock Holding History

Citadel Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Sell
50,400
-44,400
-47% -$1.65M ﹤0.01% 6381
2026
Q1 		$3.81M Buy
94,800
+38,000
+67% +$1.64M ﹤0.01% 4803
2025
Q4 		$2.88M Buy
56,800
+41,700
+276% +$1.48M ﹤0.01% 5245
2025
Q3 		$439K Sell
15,100
-25,200
-63% -$583K ﹤0.01% 9455
2025
Q2 		$949K Buy
40,300
+17,300
+75% +$389K ﹤0.01% 7220
2025
Q1 		$552K Buy
23,000
+15,800
+219% +$508K ﹤0.01% 8262
2024
Q4 		$304K Buy
7,200
+1,000
+16% +$44.3K ﹤0.01% 9626
2024
Q3 		$274K Buy
6,200
+3,800
+158% +$144K ﹤0.01% 9516
2024
Q2 		$86.8K Sell
2,400
-5,900
-71% -$234K ﹤0.01% 11112
2024
Q1 		$358K Buy
8,300
+4,500
+118% +$160K ﹤0.01% 9096
2023
Q4 		$58.4K Sell
3,800
-6,300
-62% -$80K ﹤0.01% 11621
2023
Q3 		$138K Sell
10,100
-5,400
-35% -$92.6K ﹤0.01% 10476
2023
Q2 		$249K Buy
15,500
+9,500
+158% +$85.8K ﹤0.01% 9414
2023
Q1 		$46.6K Buy
+6,000
New +$46.3K ﹤0.01% 12248

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's VERA Position: Q2 2026 in Review

Citadel Advisors sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 429,761 shares — an estimated $16M sold.

Citadel Advisors first reported a position in VERA in Q2 2021 and held it in 19 quarters. The position peaked at $49.1M in Q1 2022. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Citadel Advisors reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 429,761 Vera Therapeutics shares in Q2 2026, an estimated $16M.
  • Citadel Advisors first reported a position in Vera Therapeutics in Q2 2021 and held it in 19 quarters.
  • Citadel Advisors's Vera Therapeutics position peaked at $49.1M in Q1 2022.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.